Targeting advances in immunotherapies
Drug Discovery World
NOVEMBER 9, 2023
DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations? CL: Immunotherapies, principally anti-PD-1/-L1 checkpoint inhibitors, have shown therapeutic benefit in improving the prognosis of patients but only in a select handful of solid cancers.
Let's personalize your content